Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 143

  • 3 898 clinical trials
  • 1 548 recruiting
  • 703 conditions
  • 31 countries

Conditions in this area

703 conditions with trials, the busiest first

Non-small cell lung cancer327Breast cancer168Plasma cell myeloma164Neoplasm158Acute myeloid leukaemia132Neoplasm malignant129Colorectal cancer metastatic105Prostate cancer101Ovarian cancer91Colorectal cancer89Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Malignant melanoma79Chronic lymphocytic leukaemia77Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV57Pancreatic carcinoma57Hormone-refractory prostate cancer56Gastric cancer55Bladder cancer54Endometrial cancer53+679

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 898 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 898 clinical trials

Squamous cell carcinoma of skin

Not yet recruiting

A study of cemiplimab in patients with locally advanced cutaneous squamous cell carcinoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL

Clear cell renal cell carcinoma

Not yet recruiting

A study of pembrolizumab, belzutifan, and lenvatinib before main treatment in patients with localized kidney cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Vall D Hebron Institute Of Oncology

Medulloblastoma recurrent

Not yet recruiting

A study of RVU120 and everolimus for children with recurrent or progressive medulloblastoma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Everolimus
  • Sponsor:Instytut Pomnik Centrum Zdrowia Dziecka

Vulval cancer

Not yet recruiting

A study to evaluate the safety and effectiveness of nivolumab and imiquimod in adults with vulvar squamous cell carcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Imiquimod
  • Sponsor:Centre Leon Berard

Head and neck cancer

Not yet recruiting

Study of ezabenlimab in patients with locally advanced head and neck cancer who have remaining signs of disease after chemoradiotherapy

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ezabenlimab
  • Sponsor:Cliniques Universitaires Saint-Luc

Congenital cystic kidney disease

Not yet recruiting

A study to evaluate the safety and tolerability of azathioprine in patients with autosomal dominant polycystic kidney and liver disease

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Azathioprine
  • Sponsor:UZ Leuven

Hormone receptor positive HER2 negative breast cancer

Not yet recruiting

Study evaluating the omission of exemestane, letrozole, anastrozole, and tamoxifen in postmenopausal women with low-risk early breast cancer.

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Unicancer

Interstitial lung disease+2

Not yet recruiting

Carboplatin‑based drug combination for advanced non‑small cell lung cancer patients with interstitial lung disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Intergroupe Francophone De Cancerologie Thoracique

Plasma cell myeloma refractory

Not yet recruiting

Study of teclistamab plus autologous lymphocyte infusion in patients with relapsed or refractory multiple myeloma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Teclistamab
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus

B-cell lymphoma+1

Not yet recruiting

Comparing human normal immunoglobulin (iv) and a drug combination to prevent infections in adults with B-cell acute lymphoblastic leukemia or B-cell lymphoma treated with CAR-T cells

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Amoxicillin Sodium
  • Sponsor:Assistance Publique Hopitaux De Paris

Neoplasm

Not yet recruiting

A study to evaluate the safety and effectiveness of BMS-986523 alone or in combination with a drug combination for patients with advanced solid tumors and KRAS alterations.

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Hepatocellular carcinoma

Not yet recruiting

A study to evaluate the safety and effectiveness of PF-08634404 and ipilimumab in adults with advanced or spreading liver cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Pfizer Inc.

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Pembrolizumab462 clinical trialsCarboplatin340 clinical trialsCisplatin285 clinical trialsPaclitaxel263 clinical trialsFluorouracil237 clinical trialsOxaliplatin227 clinical trialsNivolumab217 clinical trialsDexamethasone169 clinical trialsBevacizumab163 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.